Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis

Medical and Pediatric Oncology

Volumn 34, Issue 2, 2000, Pages 117-124

  Gustafsson, Britt ^a   Christenson, Birger ^a   Gustafsson, Bertil ^b   Hjalmar, Victoria ^a   Winiarski, Jacek ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biological tumor markers; Childhood leukemia; Immunohistochemistry; MDM2; P53; Proto oncogene proteins

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ADOLESCENT; ARTICLE; CANCER RISK; CANCER SURVIVAL; CELL CYCLE; CHILD; CHILDHOOD LEUKEMIA; DOUBLE MINUTE CHROMOSOME; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LEUKEMOGENESIS; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, P53; HUMANS; INFANT; LEUKEMIA; MALE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 0033953074     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(200002)34:2<117::AID-MPO9>3.0.CO;2-8     Document Type: Article

References (28)

1. Holstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
2. Levine J, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-456.
3. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene- two products-two pathways. Trends Biochemistry Sci 1998;23:291-296.
4. Lane DP. p53, Guardian of the genome. Nature 1992;358:15-16.
5. Mashal R, Shtalrid M, Talpaz M et al. Rearrangement and expression of the p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 1990;75:180-189.
6. Sugimoto K, Toyoshima H, Sakai R et al. Mutations of the p53 gene in lymphoid leukemia. Blood 1991;77:1153-1156.
7. Gaidano G, Ballerini P, Gong J et al. p53 mutations in human lymphoid malignancies: association with Burkitt's lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci 1991;88:5413-5417.
8. Sugimoto K, Hirano N, Toyoshima H et al. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993;81:3022-3026.
9. Prococimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the haematological cell lineages. Blood 1994;84 :2391-2411.
10. Felix CA, Nau MM, Takahashi T, et al. Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin. Invest 1991;89:640-647.
11. Wada M, Bartram CR, Nakamura H, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993;82:3163-3169.
12. Blau O, Avigad S, Stark B, et al. Exon 5 mutations in the p53 gene in relapsed childhood acute lymphoblastic leukemia. Leukemia Research 1997;21:721-729.
13. Meltzer PS. MDM2 and p53: a question of balance. J Nat Cancer Inst 1994;84:1265-1266.
14. Wu X, Bayle JH, Olson D, Levine AJ. The P53 mdm2 autoregulatory feedback loop. Genes Dev 1993;7:1126-1132.
15. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM2 gene by Cchildhood acute lymphoblastic leukemia cells expressing the wild type p53gene. Blood 1995;85:1608-1614.
16. Marks DI, Kurz BW, Link PM, et al. Altered expression of p53 and mdm2 proteins at diagnosis is associated with early treatment failure in childhood acute lymhpoblastic leukemia. J Clin Oncol 1997;15:1158-1162.
17. Marks DI, Kurz B W, Link PM, et al. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996;87:1155-1161.
18. Nagai J, Kigasawa H, Koga N, et al. Clinical significance of detecting p53 protein in Burkitt lymphoma and B-cell acute lymphoblastic leukemia using immuncytochemistry. Leuk Lymphoma 1997;28:591-597.
19. Paydas S. p53 protein expression in leukemias. Acta Oncologica 1995;34:23-26.
20. Gustafsson B, Stål O, Gustafsson B. Overexpression of MDM2 in acute childhood lymhpoblastic leukemia. Ped Hematol Oncol 1998;15:519-526.
21. Gustafsson G, Langmark F, Pihkala U, de Verdier B, Lilleaas I, editors. Nordic Society of Pediatric Haematology and Oncology. Childhood Cancer in the Nordic Countries. Reykjavik: 1998, p. 79-103, p. 104-121.
22. Zhang W, Hu G, Estey E, et al. Altered confirmation of the p 53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 1992;7:1645-1647.
23. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387: 299-303.
24. Levine J. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
25. Felix CA, Hosler M, Provisor D, et al. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 1996;87: 4376-4381.
26. Martinez JC, Mateo M, Sáanchez-Beato M, et al. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative studies with p53 expression. J Pathol 1995;177: 27-34.
27. Foti A, Ahuja HG, Allen SL, et al. Correlation between molecular events in the evolution of CML to blast crisis. Blood 1991;77: 2441-2444.
28. Jonveaux Ph, Fenaux P, Quiquandon I. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 1991;6:2243-2247.